So far CIP2A has been targeted in a limited number of cancers using (1) natural compounds, (2) fusogenic-oligoarginine peptide-mediated delivery of siRNAs for gene silencing and (3) erlotinib derivatives. The gene discussed is CIP2A; the disease is cancer.